References
Xiang Z, Zhou Z, Song S, Li J, Ji J, Yan R, et al. Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways. Oncogene. 2021; 40: 5002-12.
Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science. 2009; 324: 1394-5.
Strittmatter SM. Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. Nat Med. 2014; 20: 590-1.
Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015; 20: 1027-34.
Arakelyan A, Nersisyan L, Nikoghosyan M, Hakobyan S, Simonyan A, Hopp L, et al. Transcriptome-guided drug repositioning. Pharmaceutics. 2019; 11: 677.
Li G, Ma Y, Yu M, Li X, Chen X, Gao Y, et al. Identification of hub genes and small molecule drugs associated with acquired resistance to gefitinib in non-small cell lung cancer. J Cancer. 2021; 12: 5286-95.
Xiang Z, Liu J, Shi D, Chen W, Li J, Yan R, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci. 2020; 16: 2382-91.
Han N, Hwang W, Tzelepis K, Schmerer P, Yankova E, MacMahon M, et al. Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies. Sci Adv. 2021; 7: eabh3032.
Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER, 3rd, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019; 569: 503-8.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018; 173: 400-16 e11.
Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017; 171: 1437-52 e17.
Bai R, Chen N, Chen X, Li L, Song W, Li W, et al. Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer Biol Med. 2021; 18: 1118-33.
Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011; 163: 29-43.
Ayroldi E, Cannarile L, Delfino DV, Riccardi C. A dual role for glucocorticoid-induced leucine zipper in glucocorticoid function: tumor growth promotion or suppression? Cell Death Dis. 2018; 9: 463.
Kumar KJ, Gokila Vani M, Hsieh HW, Lin CC, Liao JW, Chueh PJ, et al. MicroRNA-708 activation by glucocorticoid receptor agonists regulate breast cancer tumorigenesis and metastasis via downregulation of NF-kappab signaling. Carcinogenesis. 2019; 40: 335-48.
Shen Y, Wu YC, Gu L. Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment. Ann Transl Med. 2020; 8: 1416.
Peng R, Zhang H, Zhang Y, Wei DY. Impacts of ABCB1 (G1199A) polymorphism on resistance, uptake, and efflux to steroid drugs. Xenobiotica. 2016; 46: 948-52.
Lewis T, Truog W, Norberg M, Ballard PL, Torgerson D, Group TS. Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia. Pediatr Res. 2019; 85: 625-33.
Geng S, Lou R, Yin Q, Li S, Yang R, Zhou J. Reshaping the tumor microenvironment for increasing the distribution of glucose oxidase in tumor and inhibiting metastasis. J Mater Chem B. 2021; 9: 1424-31.
Martin JD, Panagi M, Wang C, Khan TT, Martin MR, Voutouri C, et al. Dexamethasone increases cisplatin-loaded nanocarrier delivery and efficacy in metastatic breast cancer by normalizing the tumor microenvironment. ACS Nano. 2019; 13: 6396-408.
Morrow GR, Shelke AR, Roscoe JA, Hickok JT, Mustian K. Management of cancer-related fatigue. Cancer Invest. 2005; 23: 229-39.
Lin KT, Wang LH. New dimension of glucocorticoids in cancer treatment. Steroids. 2016; 111: 84-8.
Petrelli F, Bukovec R, Perego G, Luisa R, Luciani A, Zaniboni A, et al. Association of steroid use with survival in solid tumours. Eur J Cancer. 2020; 141: 105-14.
Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci. 2021; 17: 1530-7.
Yao Y, Yao QY, Xue JS, Tian XY, An QM, Cui LX, et al. Dexamethasone inhibits pancreatic tumor growth in preclinical models: involvement of activating glucocorticoid receptor. Toxicol Appl Pharmacol. 2020; 401: 115118.
Pang JM, Huang YC, Sun SP, Pan YR, Shen CY, Kao MC, et al. Effects of synthetic glucocorticoids on breast cancer progression. Steroids. 2020; 164: 108738.
Lin KT, Sun SP, Wu JI, Wang LH. Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model. PLoS One. 2017; 12: e0178937.
Yu Y. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. Front Med. 2018; 12: 229-35.
